Drug set to rescue COVID-19 patients at IC...Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients. more ➔
Rapid antibody development to cure COVID-1...In addition to vaccination programmes, the SARS-CoV-2 pandemic requires safe and efficient treatment options for patients infected and suffering from Covid-19 disease. Virus-neutralising antibody therapeutics … more ➔
Polyphor AG bags funding for murepavadinPolyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin. more ➔
Searching for an effective treatment for C...Apogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its … more ➔
Global bioeconomy in the spotlight12 interactive workshops, five plenary sessions and more than 3,000 registered attendees – last week the Global Bioeconomy Summit brought together international experts to discuss major trends and d … more ➔
A pioneering real AI drug discovery techno...The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and … more ➔
Collaborating to accelerate vaccine manufa...Development of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate … more ➔
3,000+ experts discuss bioeconomy globallyMore than 3,000 attendees are participating in the Global Bioeconomy Summit, currently taking place virtually until 20th November. Today, the plenary program and the livestream of the conference kicked-off. more ➔
EU COVID-19 antibody ready for clinical tr...As investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing. more ➔
COVID-19: Moderna reports promising interi...After BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%. more ➔
